Introduction {#S0001}
============

It is estimated that the global proportion of individuals over 60 years will approximately double from 12% (2015 figure) to 22% in 2050.[@CIT0001] With this aging population, dementia (currently 50 million diagnosed cases globally) and depression (7% of general older adults globally) pose major public health issues.[@CIT0002] This is particularly relevant in the context of the aging population of United States (US). According to a recent estimate, the number of older adults (age ≥65 years) with dementia is expected to increase approximately two-and-half times from 5.8 million in 2020 to 13.8 million in 2050.[@CIT0003] Co-occurring physical and mental chronic conditions burden is high among older adults with dementia, with depression being one of the most prevalent chronic psychiatric conditions in this population.[@CIT0004] It is well documented that presence of depression among older adults with dementia not only decreases the quality of life (QoL), but is also associated with several negative outcomes such as faster cognitive decline, poor adherence to medications, high functional disability, increased rates of institutionalization, and mortality.[@CIT0005]--[@CIT0008]

Existing studies examining the efficacy/effectiveness of antidepressants to treat depression have shown conflicting findings. Some studies have shown positive effects[@CIT0009]--[@CIT0015] while some have shown no beneficial effects[@CIT0016]--[@CIT0018] of antidepressants to treat depression among older adults with dementia and depression. A multicenter, randomized, double-blind, placebo-controlled pragmatic trial examining the clinical effectiveness of sertraline and mirtazapine among individuals with Alzheimer's disease and co-occurring depression failed to demonstrate the clinical effectiveness of sertraline and mirtazapine compared to placebo (all three groups had normal care) in terms of reducing depression.[@CIT0019] However, trend towards the beneficial effect of antidepressants was noted in a recent meta-analysis.[@CIT0020] Moreover, a population-based retrospective cohort study utilizing the National Health Insurance medical claims data demonstrated the protective effects of antidepressants in all-cause mortality among older adults with dementia and depression.[@CIT0021] Thus, there is evidence of potential clinical benefits of antidepressants to treat depression among older adults with dementia and depression.

Currently, there are no depression treatment guidelines for older adults with dementia and MDD. In one of our previous studies,[@CIT0022] we quantified the extent of potentially inappropriate antidepressants among older adults with dementia and newly diagnosed MDD using the National Committee for Quality Assurance's (NCQA's) Healthcare Effectiveness Data and Information Set (HEDIS) guidelines for antidepressant medication management (AMM).[@CIT0023] A list of potentially inappropriate antidepressants for older adults with dementia in our recently published study[@CIT0022] was developed using the Beers criteria and Screening Tool of Older Persons' potentially inappropriate Prescriptions (STOPP) criteria.[@CIT0024],[@CIT0025] Given the evidence supporting the potential benefits of depression treatment and the serious lack of studies examining adherence to depression treatment among older adults with dementia and newly diagnosed MDD, there is a need to examine the status of depression treatment adherence in this vulnerable population. Hence, excluding the potentially inappropriate antidepressants, we sought to estimate the extent of and identify factors associated with adherence to acute and continuation phase antidepressant treatment among older adults with dementia and newly diagnosed MDD using a nationally representative sample of Medicare beneficiaries.

Methods {#S0002}
=======

Study Design {#S0002-S2001}
------------

Using Medicare 5% sample claims data (2012--2013), we conducted a retrospective cohort study.

Data Source {#S0002-S2002}
-----------

We used several data files of the Medicare 5% sample claims data (2012--2013) for the purpose of this study. Data files included in this study were: (i) inpatient; (ii) outpatient; (iii) skilled nursing facility; (iv) carrier; (v) hospice care; (vi) home health agency; (vii) Part D event (PDE); and (viii) durable medical equipment files. Longitudinal follow-up of the Medicare beneficiaries and linking different data files are achieved by a unique de-identified Medicare beneficiary identifier assigned to each beneficiary. Information available in the claims data include: dates of service provided; charge and payment amounts; medication utilization; clinical diagnosis codes; and procedure codes. Demographic (e.g. age, gender, race/ethnicity) and eligibility information are available in the Medicare Beneficiary Summary File (MBSF).

Certain important regional-level factors (such as density of psychiatrists in a zip-code area) that can influence antidepressant adherence are not available in the Medicare dataset. In order to obtain this information, we merged the Area Health Resource File (AHRF) (a publicly available county-specific data) with Medicare dataset using the Social Security Administration codes. We also merged the Medicare dataset with National Plan and Provider Enumeration System (NPPES), also referred to as the National Provider Identifier (NPI) File to obtain provider specialty information from NPIs that appear in the PDE files.

Study Sample {#S0002-S2003}
------------

We used the Centers for Medicare and Medicaid Services (CMS) Chronic Conditions Data Warehouse Condition Categories algorithm to identify beneficiaries with dementia.[@CIT0026] Older adults (age ≥65 years) with dementia comprised our study sample. The Intake Period, based on the HEDIS AMM guideline, was from May 1, 2012, through April 30, 2013.[@CIT0023] The date of the first observed prescription claim of antidepressant during the Intake Period was defined as the Index Prescription Start Date (IPSD). For inclusion in the final study sample, the Medicare beneficiaries with dementia were required to have continuous Medicare Part A, B and D enrollment and no Health Maintenance Organizations (HMO) enrollment during the 105 days pre-IPSD, on the IPSD. Additionally, for inclusion in the acute and continuation phase cohort, Medicare beneficiaries with dementia were required to have continuous enrollment throughout the acute phase (114 days post-IPSD) and continuation phase (231 days post-IPSD) respectively.

Medicare beneficiaries were also required to have negative medication history defined as 105 days of no pharmacy claim for either new or refill prescriptions for an antidepressant medication prior to IPSD. Diagnosis of MDD was identified during the 121-day period from 60 days prior to IPSD, through the IPSD, and 60 days post IPSD. Based on HEDIS recommendation, MDD was defined as primary or secondary inpatient, outpatient or carrier claim of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes of 296.2 (major depressive disorder, single episode), 296.3 (major depressive disorder, recurrent episode), 309.1 (prolonged depressive reaction), 300.4 (clinically significant depression), or 311 (depression not elsewhere classified).[@CIT0023] These ICD-9-CM codes have been used in many existing studies to identify clinically significant or major depression.[@CIT0027]--[@CIT0030] We considered 105 days before IPSD as the baseline period of our study. Exclusion criteria of our study were: (i) presence of end-stage renal disease (ESRD) at any time during the calendar year of IPSD; (ii) diagnosis of end-stage liver disease (ESLD) during baseline (iii) missing race/ethnicity information, or (iv) missing AHRF information. Additional exclusion criteria for acute phase adherence were: switch to HMO, or death or prescription claim for any inappropriate antidepressant during acute phase. For continuation phase adherence we excluded Medicare beneficiaries who switched to HMO, or died during the continuation phase or had any prescription claim of inappropriate antidepressant during continuation phase treatment. We used the MBSF to identify ESRD, while we used ICD-9-CM codes of 155.0 and 571.0--9 for ESLD identification.[@CIT0031]

Dependent Variables {#S0002-S2004}
-------------------

Adherence during acute and continuation phase depression treatment was the dependent variable for this study and was calculated based on the days of supply of antidepressants from prescription claims in the PDE file. Index antidepressants included in this study were those that are not deemed to be potentially inappropriate antidepressants according to the Beers and STOPP criteria.[@CIT0024],[@CIT0025] This list of potentially inappropriate antidepressants has been used in our previous study.[@CIT0022] Antidepressants that were included in this study based on the HEDIS guidelines are presented in [[Appendix 1](http://www.dovepress.com/get_supplementary_file.php?f=241749.docx)]{.ul}. Antidepressants were identified using the National Drug Codes available from the PDE file.

### Adherence During Acute Phase Treatment {#S0002-S2004-S3001}

According to HEDIS, adults with major depression, including older Medicare beneficiaries having dementia, should have ≥85 days of antidepressant use during the first 115 days to be adherent to the acute phase treatment.[@CIT0023]

### Adherence During Continuation Phase Treatment {#S0002-S2004-S3002}

Based on HEDIS criteria, adults with major depression, including older Medicare beneficiaries with dementia, should have ≥181 days of antidepressant use during the first 232 days to be adherent to the continuation phase treatment.[@CIT0023]

Independent Variables {#S0002-S2005}
---------------------

We included several variables in this study. Demographic characteristics consisted of age (65--74, and 75 years and older); gender (male/female); and race/ethnicity (white and others). Burden of co-occurring conditions during baseline was estimated using the Elixhauser comorbidity index.[@CIT0032] As we used all the Medicare files (excluding PDE and MBSF) to estimate Elixhauser comorbidity burden, we followed the rule-out algorithm (at least 2 diagnosis of interest that were \>30 days apart) when using the Medicare physician or outpatient files to avoid overestimation of co-occurring conditions burden; whereas for all other files, only one diagnosis claim was required.[@CIT0032],[@CIT0033] Based on an existing study, we categorized Elixhauser comorbidity score into four non-ordinal groups (0, 1, 2, and ≥3) after summing all 31 individual Elixhauser conditions.[@CIT0033] We identified baseline use of common medications that included: angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), anticoagulants, antidiabetics, antipsychotics, anxiolytics, statins, beta-blockers, calcium-channel blockers, diuretics, antiparkinsonian, and proton pump inhibitors. We identified the baseline diagnosis of Parkinson's disease (PD) using ICD-9-CM code of 332.xx.[@CIT0034],[@CIT0035] We also examined the baseline use of psychotherapy using Current Procedural Terminology (CPT) codes from existing studies (psychotherapy CPT codes are provided in [[Appendix 2](http://www.dovepress.com/get_supplementary_file.php?f=241749.docx)]{.ul}).[@CIT0036],[@CIT0037] Other variables that we included in this study were: physician specialty (specialty of the doctor that prescribed the index prescription such as Neurology, Psychiatry, General/Family, Other, and Unknown); census region (Northeast, South, Midwest, West); metropolitan residency status (metropolitan/non-metropolitan); and density of each of neurologists and psychiatrists available within the zip code. We categorized each of these densities into four groups (those with 0 and those with \>0 divided into tertiles). We also used public assistance (indicated by Medicare premiums and deductibles that are subsidized by the state to indicate the financial status of the enrollee) as one of the individual-level variables in this study.

Statistical Analysis {#S0002-S2006}
--------------------

We compared the adherent and non-adherent groups for each predictor variable by chi-square tests. To identify predictors of adherence during acute and continuation phase depression treatment, we conducted multiple logistic regression analysis. We used a conservative α=0.01 (to decrease Type I error rates) to establish statistical significance for all tests as our study included several variables. We conducted all analyses using SAS version 9.4 (SAS Institute, Cary, NC). When we merged the Medicare PDE files with the NPPES file, some of the NPIs did not match and we categorized them as unknown physician specialty. In order to examine the robustness of our base case analysis, we excluded the observations where the physician specialty was unknown and conducted a sensitivity analysis in that sample.

Results {#S0003}
=======

We present the baseline characteristics of our study sample and the comparisons between adherent and non-adherent groups during acute and continuation phase depression treatment in [Tables 1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"}, respectively. The final study sample consisted of 6239 \[adherent: N=4644 (74.44%)\] and 5617 \[adherent: N=3584 (63.81%)\] older adults with dementia and MDD during acute and continuation phase treatment, respectively. Differences in baseline characteristics between adherent and non-adherent groups during the acute phase were observed for race/ethnicity and public assistance, whereas during the continuation phase we observed differences in race/ethnicity, region and baseline antipsychotic use. For example, whites were more adherent during both acute (75.2% vs 68.0%, chi-square test: *χ^2^* = 17.16, *df*=1, p-value\<0.001) and continuation (65.0% vs 54.5%, chi-square test: *χ^2^* = 26.74, *df*=1, p-value\<0.001) phase depression treatment compared to other race/ethnic category.Table 1Baseline Characteristics of Antidepressant Adherent and Non-Adherent Groups During Acute Phase Medicare 5% Sample Claims Data (2012--2013)OverallAdherentNon-Adherentχ2*df*p-valueN = 6239%N = 4644%N = 1595%Age Group3.11810.07765--74 years98515.871172.227427.875+ years525484.2393374.9132125.1Gender0.00610.939Male157325.2117274.540125.5Female466674.8347274.4119425.6Race/Ethnicity\*17.1581\<0.001White553988.8416875.2137124.8Other70011.247668.022432.0Public Assistance\*13.5291\<0.001Yes194931.2139271.455728.6No429068.8325275.8103824.2Region8.84830.031Northeast128020.596975.731124.3South248339.8181573.166826.9Midwest172427.6131776.440723.6West75212.154372.220927.8Metropolitan Status0.13010.718Yes496079.5369774.5126325.5No127920.594774.033226.0Baseline PD5.52410.019Yes3685.929379.67520.4No587194.1435174.1152025.9Baseline Psychotherapy4.90210.027Yes77112.459977.717222.3No546887.6404574.0142326.0Provider Specialty6.51440.164General Family468275.0349374.6118925.4Neurology1522.411676.33623.7Psychiatry3756.029077.38522.7Other88914.265073.123926.9Unknown1412.39567.44632.6Density of Neurologists9.50330.0230121819.591675.230224.81167826.9124874.443025.62167426.8120471.947028.13166926.8127676.539323.5Density of Psychiatrists5.30430.151090314.566373.424026.61178028.5129872.948227.12177728.5135276.142523.93177928.5133174.844825.2ELX Index2.87030.4120103316.677274.726125.31101916.377576.124423.9298515.871772.826827.23320251.3238074.382225.7**Baseline Medication Use**ACE Inhibitors0.58210.446Yes156725.1115573.741226.3No467274.9348974.7118325.3Anticoagulants0.01010.921Yes73511.854674.318925.7No550488.2409874.5140625.5Antidiabetic0.11010.740Yes109017.580774.028326.0No514982.5383774.5131225.5Antiparkinsonian0.73310.392Yes4126.631476.29823.8No582793.4433074.3149725.7Antipsychotic2.93710.087Yes99616.076376.623323.4No524384.0388174.0136226.0Anxiolytic0.34610.556Yes101916.375173.726826.3No522083.7389374.6132725.4ARB2.32510.127Yes81113.058672.322527.7No542887.0405874.8137025.2Statin\<0.00110.994Yes223335.8166274.457125.6No400664.2298274.4102425.6PPI2.35010.125Yes184229.5134773.149526.9No439770.5329775.0110025.0Beta-Blocker3.18710.074Yes243339.0178173.265226.8No380661.0286375.294324.8CCB1.15510.283Yes146823.5107773.439126.6No477176.5356774.8120425.2Diuretic3.77110.052Yes215634.6157373.058327.0No408365.4307175.2101224.8[^1][^2] Table 2Baseline Characteristics of Antidepressant Adherent and Non-Adherent Groups During Continuation Phase Medicare 5% Sample Claims Data (2012--2013)OverallAdherentNon-Adherentχ2dfp-valueN=5617%N=3584%N=2033%Age Group5.81410.01665--74 years92516.555860.336739.775+ years469283.5302664.5166635.5Gender0.08210.775Male138324.687863.550536.5Female423475.4270663.9152836.1Race/Ethnicity\*26.7401\<0.001White498488.7323965.0174535.0Other63311.334554.528845.5Public Assistance6.43110.011Yes172130.6105661.466538.6No389669.4252864.9136835.1Region\*11.73130.008Northeast117120.878967.438232.6South221639.5138162.383537.7Midwest154727.599964.654835.4West68312.241560.826839.2Metropolitan Status0.42810.513Yes446979.6286164.0160836.0No114820.472363.042537.0Baseline PD3.34910.067Yes3396.023268.410731.6No527894.0335263.5192636.5Baseline Psychotherapy1.75910.185Yes68712.245466.123333.9No493087.8313063.5180036.5Provider Specialty5.07040.280General Family418274.5268664.2149635.8Neurology1372.49065.74734.3Psychiatry3516.223266.111933.9Other81814.649660.632239.4Unknown1292.38062.04938.0Density of Neurologists5.40730.1440110019.669763.440336.61150726.896664.154135.92150326.892961.857438.23150726.899265.851534.2Density of Psychiatrists5.73530.125081114.449761.331438.71158628.299662.859037.22160528.6105665.854934.23161528.8103564.158035.9ELX Index4.92430.177096217.158460.737839.3194916.961464.733535.3289616.058064.731635.33281050.0180664.3100435.7**Baseline Medication Use**ACE Inhibitors0.29510.587Yes142725.490263.252536.8No419074.6268264.0150836.0Anticoagulants0.02310.880Yes65011.641363.523736.5No496788.4317163.8179636.2Antidiabetics0.66310.415Yes97517.461162.736437.3No464282.6297364.0166936.0Antiparkinsonian0.18910.664Yes3766.723662.814037.2No524193.3334863.9189336.1Antipsychotic\*15.6991\<0.001Yes88715.861869.726930.3No473084.2296662.7176437.3Anxiolytic1.98910.158Yes92616.557261.835438.2No469183.5301264.2167935.8ARB2.88010.090Yes74413.245461.029039.0No487386.8313064.2174335.8Statins0.95410.329Yes203136.2127963.075237.0No358663.8230564.3128135.7PPI2.48710.115Yes165829.5103262.262637.8No395970.5255264.5140735.5Beta-Blockers1.98110.159Yes217838.8136562.781337.3No343961.2221964.5122035.5CCB2.46610.116Yes131823.581762.050138.0No429976.5276764.4153235.6Diuretic1.26210.261Yes189533.7119062.870537.2No372266.3239464.3132835.7[^3][^4]

In [Table 3](#T0003){ref-type="table"}, we present the class-based as well as individual antidepressant utilization distributions for adherent and non-adherent groups during acute and continuation phase depression treatment. We observed statistically significant differences with respect to adherence among index antidepressant classes during both acute (chi-square test: *χ^2^* = 20.7, *df*=4, p-value\<0.001) and continuation phase (chi-square test: *χ^2^* = 15.2, *df*=4, p-value=0.004) depression treatment with the antidepressant category "Other" exhibiting the highest adherence among the classes. While we did not conduct chi-square tests among the individual antidepressants to compare adherent and non-adherent groups, of the Medicare beneficiaries included in the analysis of continuation phase adherence, the most common index antidepressants were sertraline (N=1386) and citalopram (N=1381) whereas it were citalopram (N=1260) and sertraline (N=1245) for continuation phase.Table 3Description of Antidepressant Medication Initiation by Class-Level and Individuals-Level in Acute and Continuation Phase Medicare 5% Sample Claims Data (2012--2013)Acute PhaseAdherentNon-Adherentχ^2^dfp-valueN%N%Antidepressant Class\*20.7004\<0.001SSRI305575.698724.4SNRI51275.017125.0Tetracyclic62971.325328.7Phenylpiperazine28567.213932.8Others16378.44521.6Individual AntidepressantBupropion14178.33921.7Citalopram103775.134424.9Desvenlafaxine2172.4827.6Duloxetine31074.310725.7Escitalopram72076.422323.6Fluoxetine23672.68927.4Fluoxetine/olanzapine1100.0-0.0Fluvoxamine685.7114.3Mirtazapine62971.325328.7Nefazodone1100.0-0.0Selegiline133.3266.7Sertraline105676.233023.8Trazodone28467.113932.9Venlafaxine18176.45623.6Vilazodone2083.3416.7Continuation PhaseAdherentNon-Adherentχ^2^*df*p-valueN%N%Antidepressant Class\*15.19940.004SSRI236764.6129735.4SNRI40965.022035.0Tetracyclic45760.429939.6Phenylpiperazine21657.416042.6Others13570.35729.7Individual AntidepressantBupropion11871.14828.9Citalopram79963.446136.6Desvenlafaxine1973.1726.9Duloxetine24263.513936.5Escitalopram56966.129233.9Fluoxetine17961.311338.7Fluoxetine/olanzapine1100.0-0.0Fluvoxamine6100.0-0.0Mirtazapine45760.429939.6Nefazodone1100.0-0.0Selegiline-0.02100.0Sertraline81465.443134.6Trazodone21557.316042.7Venlafaxine14866.77433.3Vilazodone1669.6730.4[^5][^6]

We present the findings from multiple logistic regression analysis during acute and continuation phase depression treatment in [Tables 4](#T0004){ref-type="table"} and [5](#T0005){ref-type="table"}, respectively. During the acute phase, only race/ethnicity was significantly associated with adherence to depression treatment, with whites having 30% \[Adjusted Odds Ratio (AOR): 1.30, 99% CI: 1.02--1.66, multiple logistic regression analysis Wald χ2 = 7.99, p =0.005\] higher odds of being adherent compared to non-whites. We observed similar findings in terms of race/ethnicity during continuation phase treatment, with whites having a 49% (AOR: 1.49, 99% CI: 1.18--1.89, multiple logistic regression analysis Wald *χ*^2^ = 18.79, p\<0.001) higher chance of depression treatment adherence than non-whites. In addition, during continuation phase depression treatment, baseline antipsychotic use was associated with 43% (AOR: 1.43, 99% CI: 1.16--1.76, multiple logistic regression analysis Wald *χ*^2^ = 18.80, p\<0.001) higher odds of depression treatment adherence among older adults with dementia and newly diagnosed MDD.Table 4Predictors of Adherence During Acute Phase Depression TreatmentAOR99% CIWald χ^2^p-valueLower CLUpper CLAge Group 75+ years vs 65--74 years1.140.931.402.610.106Gender Female vs Male1.030.861.230.210.649Race/Ethnicity\* White vs Others1.301.021.667.990.005Public Assistance Yes vs No0.860.731.025.030.025Region2.930.403 Northeast vs South1.030.831.29 West vs South1.000.781.29 Midwest vs South1.130.931.37Metropolitan Status Yes vs No1.020.801.290.040.845Baseline Parkinson's Disease Yes vs No1.390.922.104.160.041Baseline Psychotherapy Yes vs No1.220.951.564.310.038Provider Specialty5.200.268 Neurology vs General/Family1.050.631.75 Psychiatry vs General/Family1.100.781.54 Other vs General/Family0.920.741.14 Unknown vs General/Family0.710.441.14Density of Neurologists10.540.015 1 vs 00.810.601.11 2 vs 00.690.500.96 3 vs 00.830.581.18Density of Psychiatrists10.190.017 1 vs 01.140.831.56 2 vs 01.441.012.05 3 vs 01.300.891.90ELX Index2.600.458 1 vs 01.090.831.42 2 vs 00.920.711.20 ≥3 vs 01.010.801.26ACE Inhibitors Yes vs No0.970.811.170.150.695Anticoagulant Yes vs No1.010.801.290.020.898Antidiabetic Yes vs No1.080.871.330.800.371Antiparkinsonian Yes vs No0.940.651.370.170.679Antipsychotic Yes vs No1.180.951.463.760.053Anxiolytic Yes vs No0.970.791.190.120.728ARB Yes vs No0.940.741.190.490.482Statin Yes vs No1.070.901.260.960.327PPI Yes vs No0.940.801.120.790.375Beta-blocker Yes vs No0.920.781.081.790.181CCB Yes vs No0.980.821.180.070.795Diuretic Yes vs No0.920.781.091.490.222[^7][^8] Table 5Predictors of Adherence During Continuation Phase Depression TreatmentAOR99% CIWald χ^2^p-valueLower CLUpper CLAge Group 75+ years vs 65--74 years1.160.951.423.850.050Gender Female vs Male1.050.891.250.610.435Race/Ethnicity\* White vs Others1.491.181.8918.79\<0.001Public Assistance Yes vs No0.930.791.101.100.294Region3.970.265 Northeast vs South1.160.941.43 West vs South0.990.771.26 Midwest vs South1.070.891.28Metropolitan Status Yes vs No0.990.781.240.020.886Baseline Parkinson's Disease Yes vs No1.360.931.994.280.039Baseline Psychotherapy Yes vs No1.030.821.300.110.738Provider Specialty5.220.266 Neurology vs General/Family1.090.671.76 Psychiatry vs General/Family1.010.741.39 Other vs General/Family0.840.691.04 Unknown vs General/Family0.900.561.46Density of Neurologists4.640.201 1 vs 00.870.651.17 2 vs 00.790.581.09 3 vs 00.900.641.25Density of Psychiatrists7.740.052 1 vs 01.190.881.62 2 vs 01.401.001.97 3 vs 01.260.871.82ELX Index7.210.066 1 vs 01.220.951.56 2 vs 01.230.951.58 ≥3 vs 01.231.001.52ACE Inhibitors Yes vs No1.000.831.190.000.945Anticoagulant Yes vs No0.970.771.230.090.768Antidiabetic Yes vs No1.020.831.240.040.840Antiparkinsonian Yes vs No0.790.561.123.020.082Antipsychotic\* Yes vs No1.431.161.7618.80\<0.001Anxiolytic Yes vs No0.910.751.101.670.196ARB Yes vs No0.940.751.180.470.494Statin Yes vs No1.000.851.170.000.981PPI Yes vs No0.940.801.110.960.327Beta-Blocker Yes vs No0.930.801.091.260.262CCB Yes vs No0.950.801.130.570.450Diuretic Yes vs No0.970.821.140.280.596[^9][^10]

We conducted a sensitivity analysis by removing the observations where the physician specialty was unknown (N~Acute~=141 and N~Continuation~=129). Findings from these sensitivity analyses are presented in [[Supplemental Tables 1](http://www.dovepress.com/get_supplementary_file.php?f=241749.docx)]{.ul}--[[5](http://www.dovepress.com/get_supplementary_file.php?f=241749.docx)]{.ul}. Overall, the findings from sensitivity analyses were similar to our primary analysis except that the density of neurologists and psychiatrists was also significantly associated with antidepressant adherence during acute phase treatment.

Discussion {#S0004}
==========

To the best of our knowledge, this is the first study examining the adherence to antidepressants during both acute and continuation phases of depression treatment among older adults with dementia and MDD in a nationally representative sample of Medicare beneficiaries. This study uniquely contributes to the existing knowledge by informing us about the current state of antidepressant adherence as well as identifying the modifiable and non-modifiable factors associated with antidepressant adherence in this vulnerable population in the US. It is critical to identify the factors associated with antidepressant adherence in order to develop appropriate interventions to improve adherence that can lead to better health outcomes (e.g. antidepressant use showed protective effect against all-cause mortality in a similar population in Taiwan[@CIT0021]).

Though our study categorized race/ethnicity into only 2 groups -- White (Non-Hispanic Whites) and Other (non-White race and Hispanics), minority older adults with dementia were at higher risk of non-adherence with depression treatment compared with white older adults. This data provides additional evidence about health disparities among older people with dementia and depression, supplementing our previous research that showed minority older patients received significantly less depression treatment (antidepressants alone or antidepressant + psychotherapy) compared with white older patients.[@CIT0038] Such treatment disparity has been a consistent finding across several studies.[@CIT0039]--[@CIT0043] In fact, the research that has found evidence of treatment disparities of minority patients with depression has accumulated over more than 20 years.[@CIT0044] Examples of reasons for depression treatment disparities include access issues (affordability, transportation), health literacy, cultural factors, patient beliefs about disease and medications, and patient--provider relationship.[@CIT0044] Furthermore, a recent study by our research team that evaluated the appropriateness of antidepressant selection for the older population having dementia and depression found almost equivalent rates of inappropriate antidepressant initiation between White subjects (7.6%) and their non-White counterparts (7.5%).[@CIT0022] Although race/ethnicity did not differ between inappropriate and appropriate antidepressants initiated by the study sample in our previous study,[@CIT0022] we know that not as many minority older patients are initiated on an antidepressant; thus, the similar rate of inappropriate prescribing was an unfortunate finding.

At the same time, there is a lack of research examining depression treatment adherence among older adults with dementia. A wide range of adherence (20--80%) has been reported for depression medications, while poorer adherence rates, along with lower social support, greater limitations with daily living activities and higher baseline depression scores, have been associated with higher 12-month depression scores among older adults.[@CIT0045] In the current study, non-Whites exhibited a higher risk of depression medication non-adherence than Whites among older adults with dementia and MDD. Because multiple factors contribute to depression medication non-adherence,[@CIT0046] there likely are several reasons for racial/ethnic differences in adherence, particularly among older patients with dementia. A study showed that African Americans and Latino patients accepted treatment for depression less often than White patients.[@CIT0047] Another study found that African Americans reported greater concerns about depression treatment.[@CIT0048] In the same study, White women had significantly higher antidepressant adherence compared to African-American women, and the belief about the importance of antidepressants and fewer concerns regarding antidepressants were associated with higher adherence. This study suggested that interventions targeting improved patient-provider communication, and culturally sensitive education and motivational enhancement may improve depression medication adherence.[@CIT0048]

Above mentioned gaps and disparities exist in the presence of no clear clinical guideline on treating depression among older adults with dementia. Therefore, a treatment guideline tailored to older patients with dementia and MDD is critically needed. Such clinical guidelines should emphasize appropriate antidepressant prescribing for older adults with dementia and emphasize treating minority patients as well as the importance of adherence. One perspective recommended research into help-seeking behaviors by individuals that may uncover cultural and contextual factors that influence treatment decisions.[@CIT0044] This seems to be a valuable research direction since beliefs about health and medications, social support, and environmental barriers can determine depression treatment and adherence as described in the above sections. To reduce racial and ethnic disparities in antidepressant adherence among older people with dementia and MDD, an innovative and effective intervention is warranted that addresses barriers specific to minority populations, including cultural beliefs. In addition, though our study subjects were community-dwelling, because there are patients with dementia of varying degrees in the communities across the US, it is important to involve care partners in interventions to enhance adherence.

A surprising finding from the present study is that older adults with dementia and MDD who used antipsychotics had higher antidepressant adherence compared with those who did not use antipsychotics. The difficulty of interpreting this result is that claims for antipsychotics in the data cannot be linked to a particular diagnosis, and antipsychotics may be used as an adjunctive treatment of depression or for behavioral symptoms related to dementia, in addition to psychiatric illnesses such as schizophrenia and bipolar disorder. Also, we do not have severity information related to depression or dementia in Medicare claims data. Thus, we can only guess what might be the reason for the difference. A presumption is that if study subjects' depression was better controlled due to the use of adjunct antipsychotics, their improved condition may have led to better medication adherence of antidepressants. Similarly, if the study patients' dementia-related behavioral symptoms, such as hyperactivity or agitation, were improved due to their antipsychotic use, medication adherence may have improved as a consequence. Therefore, future studies should further explore the relationship between antipsychotic use and antidepressant adherence among older adults with dementia and MDD to confirm our findings. Moreover, factors driving the relationship may be investigated and included in building an optimal adherence intervention for older adults with dementia and depression.

A higher percentage of older adults with dementia and newly diagnosed MDD were adherent to depression treatment during the acute phase compared to the continuation phase, which is unsurprising because the acute phase is a subset of the continuation phase. This finding is reflective of previous studies demonstrating many patients do not continue treatment for the recommended length of time in the continuation phase of treatment.[@CIT0049]--[@CIT0053] For example, a study by Akincigil et al found that 51% of privately insured patients diagnosed with depression were adherent to depression treatment during the acute phase, but this dropped to 42% being adherent in the continuation phase.[@CIT0049] The goal of acute-phase treatment is to relieve symptoms of depression, while the continuation phase is meant to prevent relapse.[@CIT0054] Since symptoms tend to resolve during the acute treatment phase, it makes sense that some patients choose to discontinue treatment during the continuation phase. This can occur if patients no longer understand the need to continue treatment when they are feeling better. In fact, lack of patient education regarding the duration of therapy has been found to be one of the most important causes of early treatment discontinuation.[@CIT0055] Patients may also wish to be on fewer medications and see the resolution in their depressive symptoms as an opportunity to reduce the number of medications they are taking.

In our study, Medicare beneficiaries who initiated on antidepressants in the "Others" category were more likely to be adherent compared to Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), tetracyclic and phenylpiperazine antidepressants. This may be due to differences in the side-effect profiles of the different antidepressant classes. For example, bupropion is often prescribed for patients who are more distressed by having low energy, which is a common symptom in both dementia and depression.[@CIT0056] This is an example of how medication side-effects can be used to help target specific symptoms that are common in this patient population. SSRIs and SNRIs tend to have milder side-effects,[@CIT0057] meaning it may be more difficult for patients to notice acute changes when starting these medication classes. As antidepressants often take weeks to become efficacious,[@CIT0057] it can be discouraging for patients/caregivers to not notice any changes during the first few weeks of treatment, which may consequently lead to early treatment discontinuation. However, medications like bupropion may lead to certain symptoms improving more quickly[@CIT0058] (e.g. fatigue), resulting in patients/caregivers feeling more hopeful.

Findings from our main analysis were similar to the sensitivity analysis except that both the density of neurologist and density of psychiatrist showed a significant negative and positive association with antidepressant adherence during the acute phase of depression treatment. While it is challenging to explain these findings based on our data, we can speculate that early and close access to psychiatrists during the acute phase of depression treatment may help in improving antidepressant adherence among older adults with dementia and depression. Future research should investigate the effect of the density of specialists on antidepressant adherence in more detail.

Some of the strengths of the current study are the possibility of generalizability of our study findings due to the use of a large nationally representative sample of Medicare beneficiaries, absence of recall bias and utilization of a strong depression treatment framework. A few limitations such as possibility of coding error (as with any secondary database), use of prescription claims to measure adherence and lack of severity measure if dementia and depression in claims data. Moreover, the independent variables examined for being the predictors of adherence to antidepressants in our study were limited to the availability of these variables in the datasets; there could be other factors (such as caregiver effect) that influence the antidepressant adherence in our study sample. Furthermore, it should be noted that antidepressants can be used to treat other conditions such as sedation, agitation, sleep and appetite stimulation but the exact reason for antidepressant use cannot be determined from the Medicare claims data. And finally, given the range of years of data (2012--2013) used in this study, it may not represent the current status of depression treatment among Medicare beneficiaries with dementia and MDD.

Conclusion {#S0005}
==========

Approximately 74% and 64% of older adults with dementia and MDD were adherent to acute and continuation phase antidepressant treatment in this nationally representative sample of Medicare beneficiaries. Race/ethnicity was significantly associated with adherence during both acute and continuation phases.
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[^1]: **Notes:** Analysis based on 6239 (4644 adherent and 1595 non-adherent) older adults with dementia and newly diagnosed major depression. Results are based on chi-square analysis. In terms of the density of neurologists and psychiatrists, the category 0 represents zero neurologists/psychiatrists in the zip-code and the categories 1, 2, and 3 represent the first, second, and third tertiles, respectively, of non-zero densities. \*Represents statistical significance (p-value \<0.01).

[^2]: **Abbreviations:** *df*, degrees of freedom; ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; PPI, proton pump inhibitor; CCB, calcium channel blockers; ELX, Elixhauser; PD, Parkinson's disease.

[^3]: **Notes:** Analysis based on 5617 (3584 adherent and 2033 non-adherent) older adults with dementia and newly diagnosed major depression. Results are based on chi-square analysis. In terms of the density of neurologists and psychiatrists, the category 0 represents zero neurologists/psychiatrists in the zip-code and the categories 1, 2, and 3 represent the first, second, and third tertiles, respectively, of non-zero densities. \*Represents statistical significance (p-value\<0.01).

[^4]: **Abbreviations:** *df*, degrees of freedom; ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; PPI, proton pump inhibitor; CCB, calcium channel blockers; ELX, Elixhauser; PD, Parkinson's disease.

[^5]: **Notes:** Analysis based on 6239 (4644 adherent and 1595 non-adherent) and 5617 (3584 adherent and 2033 non-adherent) older adults with dementia and newly diagnosed major depression during acute and continuation phase depression treatment. Chi-square analysis was conducted only on the overall antidepressant classes between adherent and Non-adherent groups during acute and continuation phase depression treatment. \*Represents statistical significance (p-value\<0.01).

[^6]: **Abbreviations:** SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin--norepinephrine reuptake inhibitor.

[^7]: **Notes:** Analysis based on 6239 (4644 adherent and 1595 non-adherent) older adults with dementia and newly diagnosed major depression. Results are based on multiple logistic regression analysis. In terms of the density of neurologists and psychiatrists, the category 0 represents zero neurologists/psychiatrists in the zip-code and the categories 1, 2, and 3 represent the first, second, and third tertiles, respectively, of non-zero densities. Global Wald chi-square was significant, χ2 ~(35)~ = 76.208, p \< 0.001. \*Represents statistical significance (p-value \<0.01).

[^8]: **Abbreviations:** AOR, adjusted odds ratio; CI, confidence intervals; ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; PPI, proton pump inhibitor; CCB, calcium channel blockers; ELX, Elixhauser.

[^9]: **Notes:** Analysis based on 5617 (3584 adherent and 2033 non-adherent) older adults with dementia and newly diagnosed major depression. Results are based on multiple logistic regression analysis. In terms of the density of neurologists and psychiatrists, the category 0 represents zero neurologists/psychiatrists in the zip-code and the categories 1, 2, and 3 represent the first, second, and third tertiles, respectively, of non-zero densities. Global Wald chi-square was significant, *χ*^2^ ~(35)~ = 91.543, p \< 0.001. \*Represents statistical significance (p-value\<0.01).

[^10]: **Abbreviations:** AOR, adjusted odds ratio; CI, confidence intervals; ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; PPI, proton pump inhibitor; CCB, calcium channel blockers; ELX, Elixhauser.
